

JC09 Rec'd PCT/PTO 01 JUN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Michael L. KING**Serial No.: **To Be Assigned**

Group Art Unit:

File Date: **Concurrently Herewith**

Examiner:

For: **DRUG DELIVERY SYSTEM WITH VENTED MOUTHPIECE**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

☒ Copies of the references are enclosed.

☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))

☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or

(2) a notice of allowance under § 1.311, whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No. _____.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No. 07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Michael Strickland
Registration No. 47,115

Date: June 1, 2005
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9024
Facsimile: (919) 483-7988

10/537085

JC09 Re PCT/PTO 31 JUN 2005 Page 1 of 2

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENTATTORNEY DOCKET NO.
PU4927USWSERIAL NO.
To Be Assigned

APPLICANT: Michael L. KING

FILING DATE:
Concurrently Herewith

GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	4,335,121	06/15/1982	PHILLIPPS, et al.			
	2.	4,364,923	12/21/1982	COOK, et al.			
	3.	4,627,432	12/09/1986	NEWELL, et al.			
	4.	4,778,054	10/18/1988	NEWELL, et al.			
	5.	4,811,731	03/14/1989	NEWELL, et al.			
	6.	4,922,474	05/01/1990	GROOTHUIS			
	7.	5,035,237	07/30/1991	NEWELL, et al.			
	8.	5,126,375	06/30/1992	SKIDMORE, et al.			
	9.	5,225,445	07/06/1993	SKIDMORE, et al.			
	10.	5,270,305	12/14/1993	PALMER			
	11.	5,290,815	03/01/1994	JOHNSON, et al.			
	12.	5,590,645	01/07/1997	DAVIES, et al.			
	13.	5,658,549	08/19/1997	AKEHURST, et al.			
	14.	5,674,471	10/07/1997	AKEHURST, et al.			
	15.	5,674,472	10/07/1997	AKEHURST, et al.			
	16.	5,676,929	10/14/1997	AKEHURST, et al.			
	17.	5,860,419	01/19/1999	DAVIES, et al.			
	18.	5,873,360	02/23/1999	DAVIES, et al.			
	19.	6,032,666	03/07/2000	DAVIES, et al.			
	20.	6,119,853	09/19/2000	GARRILL, et al.			
	21.	6,131,566	10/17/2000	ASHURST, et al.			
	22.	6,143,277	11/07/2000	ASHURST, et al.			
	23.	6,149,892	11/21/2000	BRITTO			
	24.	6,170,717	01/09/2001	GIOVANNI, et al.			
	25.	6,179,118	01/30/2001	GARRILL, et al.			
	26.	6,238,647	05/29/2001	AKEHURST, et al.			
	27.	6,251,368	06/26/2001	AKEHURST, et al.			
	28.	6,253,762	07/03/2001	BRITTO			
	29.	6,303,103	10/16/2001	AKEHURST, et al.			
	30.	6,309,624	10/30/2001	SAPSFORD, et al.			
	31.	6,315,112	11/13/2001	GARRILL, et al.			
	32.	6,315,173	11/13/2001	GIOVANNI, et al.			
	33.	6,318,603	11/20/2001	BURT			
	34.	6,378,519	04/30/2002	DAVIES, et al.			
	35.	6,390,088	05/21/2002	NOHL, et al.			
	36.	6,474,331	11/05/2002	RAND, et al.			
	37.	6,792,945	09/21/2004	DAVIES, et al.			
	38.	Des 299,066	12/20/1988	NEWELL, et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	39.	00/50112	08/31/2000	PCT		

Continue on page

Express Mail Label No.
EV 332064990 US

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
40.	http://www.aaaai.org/patients/publicedmat/tips/inhaledmedications.stm , pp.1-3, 1996
41.	http://www.asthma-education.com/howto01.html , pp.1-3, 2001
42.	http://www.starbright.org/schoolasthma/pdf/mdi_white_paper.pdf , pp.1-2, 2002
43.	http://www.keepkidshealthy.com/asthma/using_a_mdi.html , pp.1-2, 1999
44.	http://shs.unc.edu/medservices/specialty_services/asthma/inhaler.html , pp.1-4, September 8, 2003
Continue on page _____	
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	